Argus Research Upgrades Biogen to Buy, Announces $280 Price Target
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsUpgradesPrice Target
Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.
Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.